Atopic dermatitis is a chronic inflammatory disease of the skin, which is characterized by itching, erythema, and eczematous lacerations. It affects about 10 % of adults and approximately 15-20 % of children worldwide. As a result of genetic, immunologic, and environmental factors, the disease manifests itself with the impaired stratum corneum barrier and then immunological responses. Topical administration of corticosteroids and calcineurin inhibitors are currently used as the first strategy in the management of the disease. However, they have low skin bioavailability and some side effects. The nanocarriers as novel drug delivery systems could overcome limitations of conventional dosage forms, owing to increment of poorly soluble drug' solubility, then its thermodynamic activity and, consequently, its skin permeation. Also, side effects of the drug substances on the skin could be reduced by the nano-sized drug delivery systems due to encapsulation of the drug in the nanocarriers and targeted drug delivery of drug substances to the inflammated skin areas. Thereby, there have been available numerous research studies and patents regarding the use of nanocarriers in the management of atopic dermatitis. This review focuses on the mechanism of disease and development of nanocarrier based on novel drug release systems in the management of atopic dermatitis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2174/1872211314999200819152450 | DOI Listing |
Int J Biol Macromol
January 2025
Department of Dermatology, the Affiliated Hospital of Guilin Medical University, Guilin Medical University, Guilin, China. Electronic address:
Many atopic dermatitis (AD) patients have suboptimal responses to Dupilumab therapy. This study identified key genes linked to this resistance using multi-omics approaches to benefit more patients. We selected a prospective cohort of 54 CE treated with Dupilumab from the GEO database.
View Article and Find Full Text PDFInt Immunopharmacol
January 2025
School of Medicine, Fu Jen Catholic University, New Taipei City 24205, Taiwan; PhD Program in Pharmaceutical Biotechnology, Fu Jen Catholic University, New Taipei City 24205, Taiwan; School of Pharmacy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan. Electronic address:
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by itching and redness, affecting individuals of all ages and significantly impairing their quality of life. The prevalence of AD is rising, posing serious health concern. Relief of itching is a primary treatment objective; however, steroid treatments can lead to adverse effects, including skin barrier thinning.
View Article and Find Full Text PDFJ Dermatol
January 2025
Department of Dermatology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan.
Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, we investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. Our findings revealed that cases who discontinued treatment with nemolizumab had more severe erythema and edema/papulation on the trunk than those who continued nemolizumab.
View Article and Find Full Text PDFSisli Etfal Hastan Tip Bul
December 2024
Department of Dermatology and Venereology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
Objectives: Atopic skin plays a significant etiological role in the development of prurigo nodularis (PN). In addition to atopic dermatitis (AD), atopic skin diathesis without eczema can also contribute to the development of PN due to its association with itching. This study aims to evaluate PN in terms of AD/atopic skin diathesis, associated comorbidities, and clinical findings.
View Article and Find Full Text PDFJ Cosmet Dermatol
January 2025
Małopolska Centre of Biotechnology, Stem Cell Laboratory, Jagiellonian University, Kraków, Poland.
Objective: To present and analyze eight clinical cases illustrating the use of rose stem cell-derived exosomes (RSCEs) in treating various dermatological conditions and to review current literature on plant-derived exosomes in medicine and dermatology.
Background: RSCEs possess low cytotoxicity, high biocompatibility, and effective cellular uptake, making them promising agents for dermatological therapies. A literature review included in the introduction and discussion covers the broader role of plant-derived exosomes, highlighting their therapeutic potential in skin treatment.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!